Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 50 28 versus LO MALMOREDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 50 28 versus LO MALMOREDE.
DEMULEN 1/50-28 vs LO-MALMOREDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: Ethinyl estradiol and ethynodiol diacetate suppress gonadotropin secretion (LH, FSH) via negative feedback, inhibiting ovulation. Ethynodiol diacetate also increases cervical mucus viscosity and induces endometrial changes.
LO-MALMOREDE is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety by activating GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system.
One tablet orally once daily for 28 consecutive days per cycle.
Adults: 10 mg orally once daily, titrated to 20 mg once daily after 2 weeks if tolerated.
None Documented
None Documented
Ethinylestradiol: terminal elimination half-life ~13-27 hours (mean ~17 hours); ethynodiol diacetate (as norethindrone): terminal elimination half-life ~8-11 hours; clinical context: achieved steady-state within 5-10 days; accumulation not significant due to dose interval.
Terminal elimination half-life is approximately 4-6 hours; prolonged to 12-18 hours in moderate-to-severe renal impairment, requiring dose interval extension.
Ethinylestradiol and ethynodiol diacetate are extensively metabolized; urinary excretion accounts for ~40% of ethinylestradiol metabolites and ~50-60% of ethynodiol diacetate metabolites; fecal excretion accounts for ~30% of ethinylestradiol metabolites and ~35% of ethynodiol diacetate metabolites; biliary excretion contributes to enterohepatic circulation.
Primarily renal (75-90% unchanged); renal clearance approximates GFR, with dose adjustment needed for CrCl <30 mL/min. Biliary/fecal excretion accounts for <10%.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive